REG - N4 Pharma PLC - in-vitro siRNA update

N4 PharmaAnnouncement

15/02/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240215:nRSO1891Da&default-theme=true

RNS Number : 1891D  N4 Pharma PLC  15 February 2024

15 February 2024

N4 Pharma plc

 ("N4 Pharma" or the "Company")

 

in-vitro siRNA update

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing
Nuvec®, a novel delivery system for cancer treatments, gene therapy and
vaccines, is pleased to provide a further encouraging update on its ongoing in
vitro siRNA research work.

 

The Company has now completed its in-vitro experiments combining EGFR
(epidermal growth factor receptor) and PLK1 (Polo Like Kinase 1) siRNA
molecules onto the same Nuvec® nanoparticle and testing it in PC9 lung cancer
cells.

 

The work clearly shows that there is a strong beneficial effect at 48 hours on
cellular inhibition compared to single dose siRNA, by combining both EGFR and
PLK1 onto the same particle.

 

Specifically, when cells were treated with the highest dose of 75nanomolars
(nm) of single loaded EGFR siRNA, cell viability after 48 hours dropped to
38%. When cells were treated with 75nm of single loaded PLK1 siRNA cell
viability dropped to 33%, yet when 75nm of EGFR and PLK1 were combined
together cell viability dropped to 19%.

 

The cellular inhibition effect increases over time up to 48 hours and
increases with the amount of siRNA applied. The experiments were carried out a
number of times showing a consistent effect.

 

The Company will now expand this work by testing knockdown of EGFR alongside
BRD4 (Bromodomain-containing-protein 4) and extend the EGFR/PLK1 data in a
different cell line.

 

Nigel Theobald, Chief Executive Officer of the Company, commented:

 

"The work we are doing on multiple loading of siRNA onto one nanoparticle is
extremely encouraging and is showcasing the versatility of our Nuvec®
delivery system.

 

"This ability to be able to knockdown two independent pathways leading to a
positive added impact is an innovative approach in developing novel cancer
treatments aimed at reducing the ability for tumour escape.  We will continue
to present this data to potential licensing partners as all this work
strengthens the potential for collaboration opportunities."

 

 

For more information please contact:

 

 N4 Pharma plc

 Nigel Theobald, CEO                                                  Via N4 Pharma Investor Hub

 Luke Cairns, Executive Director

 Engage with us directly at N4 Pharma Investor Hub                    Sign up at investors.n4pharma.com (https://investors.n4pharma.com/)

 To hear more, visit                                                  https://investors.n4pharma.com/link/NPwNAr
                                                                      (https://investors.n4pharma.com/link/NPwNAr)
 SP Angel Corporate Finance LLP                                       Tel: +44(0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Caroline Rowe/Kasia Brzozowska (Corporate Finance)

 Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
 Turner Pope Investments (TPI) Limited                                Tel: +44(0)20 3657 0050

 Joint Broker

 Andy Thacker

 James Pope
 IFC Advisory Ltd                                                     Tel: +44(0)20 3934 6630

 Financial PR

 Graham Herring

 Zach Cohen

Glossary

siRNA: silencing RNA / short interfering RNA

EGFR: epidermal growth factor receptor, is found on the surface of some normal
cells and is involved in cell growth. It may also be found at high levels on
some types of cancer cells, which causes these cells to grow and divide.

Polo-like kinase 1 (PLK1) plays an important role in the initiation,
maintenance, and completion of mitosis

 

Mitosis is the process by which a cell replicates its chromosomes and then
separates them, producing two identical nuclei in preparation for cell
division.

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery
system for oncology, gene therapy and vaccines using its unique silica
nanoparticle delivery system called Nuvec® and Liptide, a unique
peptide/lipid delivery system via its subsidiary Nanogenics.

 

N4 Pharma's business model is to partner with companies developing products in
these fields to use Nuvec® or Liptide® as the delivery vehicle for these
products. As these products progress through pre‐clinical and clinical
programs, N4 Pharma will seek to receive upfront payments, milestone payments
and ultimately royalty payments once products reach the market.

 

For further information on the Company visit www.n4pharma.com
(http://www.n4pharma.com) or sign up at investors.n4pharma.com
(https://investors.n4pharma.com/) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDFLFLTFIISLIS